Cryoport, Inc. (CYRX) Q2 2024 10-Q Summary
Business Context and Reporting Period
This summary covers Cryoport, Inc.'s unaudited financial results for the quarterly period ended June 30, 2024. Cryoport is a global provider of temperature-controlled supply chain solutions, bio-storage, and cryogenic systems for the life sciences industry, operating over 50 strategic locations worldwide. The company reported a significant net loss driven primarily by a non-cash goodwill impairment charge.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | Q2 2023 (3 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $57.6 million | $112.2 million | $57.0 million | $119.8 million |
| Gross Margin | $25.2 million (43.7%) | $47.0 million (41.9%) | $24.7 million (43.4%) | $51.8 million (43.2%) |
| Net Loss | $(78.0) million | $(96.9) million | $(18.4) million | $(23.9) million |
| Diluted EPS | $(1.62) | $(2.05) | $(0.42) | $(0.58) |
| Cash & Equivalents | $46.5 million (as of June 30, 2024) | |||
| Short-term Investments | $380.7 million (as of June 30, 2024) | |||
| Working Capital | $442.1 million (Current Assets $502.0M - Current Liabilities $59.9M) | |||
| Convertible Senior Notes | $369.9 million (Carrying Value) |
Material Changes vs. Prior Period
- Revenue: Q2 2024 revenue increased 1.0% year-over-year to $57.6 million. This was driven by an 8.1% increase in Life Sciences Services revenue ($38.0 million), offset by a 10.4% decline in Life Sciences Products revenue ($19.6 million) due to decreased demand for cryogenic systems, particularly in China.
- Impairment Loss: The company recorded a non-cash impairment loss of $63.8 million in Q2 2024. This consisted of a $54.6 million full impairment of goodwill related to the MVE Biological Solutions reporting unit and a $9.0 million impairment of trademarks, triggered by a sustained decrease in share price and reduced projected operating performance.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased 7.3% to $36.0 million, largely due to the absence of $3.8 million in integration costs incurred in 2023 for a strategic opportunity that did not materialize.
- Debt Repurchases: The company repurchased $10.0 million in aggregate principal amount of its 2026 Senior Notes in May 2024, recognizing a gain on extinguishment of debt of $1.2 million.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue incurring significant expenses and operating losses in the near term while investing in new supply chain initiatives and geographic expansion. They believe current cash, short-term investments, and projected cash flows will satisfy operational requirements for at least the next 12 months.
- Strategic Initiatives: The company is scaling the IntegriCell platform (expected launch Q4 2024) and expanding facilities in Houston, Texas, and Liège, Belgium. Cryoport supported 684 clinical trials globally as of June 30, 2024, including 76 in Phase 3.
- Subsequent Events (Debt Repurchase): In August 2024, the company entered into agreements to repurchase approximately $160.0 million of its 2026 Senior Notes for $141.6 million under a new $200 million repurchase program authorized in August 2024.
- Risks: Key risks include foreign currency fluctuations (impacting EMEA and APAC revenues), inflationary pressures on labor and materials, and the potential for further goodwill impairments if market conditions or operating performance deteriorate.
Investor Verification Checklist
- Impairment Details: Verify the specific assumptions used in the MVE goodwill impairment test (discount rate of 12.5%, projected cash flows) and the likelihood of future impairments.
- Product Demand Recovery: Assess the trajectory of Life Sciences Products revenue, specifically the recovery of demand for cryogenic systems in the China market.
- Debt Reduction Impact: Confirm the closing of the $160 million debt repurchase announced in August 2024 and its impact on future interest expense and leverage ratios.
- Liquidity Runway: Review the burn rate relative to the $427 million in total liquid assets (cash + short-term investments) to validate the 12-month liquidity assertion.
- Non-GAAP Measures: Review the reconciliation of Adjusted EBITDA, which was negative $3.8 million for Q2 2024, to understand core operating performance excluding the impairment charge.